Journal
FUTURE MICROBIOLOGY
Volume 13, Issue 2, Pages 151-163Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fmb-2017-0175
Keywords
AMPs; antibiofilm activity; antimicrobial peptides; multidrug-resistant Pseudomonas aeruginosa; ocellatin peptides; ocellatin-PT3; synergy
Categories
Funding
- European Union (FEDER funds through COMPETE)
- National Funds (FCT, Fundacao para a Ciencia e Tecnologia) [UID/QUI/50006/2013-POCI/01/0145/FEDER/007265]
- Programa Operacional Regional do Norte under the Quadro de Referencia Estrategico Nacional (QREN) [ON.2 - O Novo Norte]
- Fundo Europeu de Desenvolvimento Regional (Feder) [NORTE-01-0145-FEDER-000024, NORTE-01-0145-FEDER-000011, NORTE-07-0161-FEDER-000111]
- FCT [SFRH/BD/97995/2013]
- POPH-QREN-Tipologia 4.1-Formacao Avancada
- Fundo Social Europeu and Ministerio da Ciencia, Tecnologia e Ensino Superior
Ask authors/readers for more resources
To test ocellatin peptides (ocellatins-PT2-PT6) for antibacterial and antibiofilm activities and synergy with antibiotics against Pseudomonas aeruginosa. Materials & methods: Normal- and checkerboard-broth microdilution methods were used. Biofilm studies included microtiter plate-based assays and microscopic analysis by confocal laser scanning microscopy and atomic force microscopy. Results: Ocellatins were more active against multidrug-resistant isolates of P. aeruginosa than against susceptible strains. Ocellatin-PT3 showed synergy with ciprofloxacin and ceftazidime against multidrug-resistant isolates and was capable of preventing the proliferation of 48-h mature biofilms at concentrations ranging from 4 to 8x the MIC. Treated biofilms had low viability and were slightly more disaggregated. Conclusion: Ocellatin-PT3 may be promising as a template for the development of novel antimicrobial peptides against P. aeruginosa. [GRAPHICS] .
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available